Cardiac Biomarkers Market: By Biomarker Type, Ischemia Modified Albumin, Creatine Kinase, Myoglobin, Troponins, and Others), By Disease Type, By End User, and Region Forecast 2020-2031
Cardiac Biomarkers Market size was valued at US$ 14.4 billion in 2024 and is expected to reach US$ 28.2 billion by 2031, growing at a significant CAGR of 10.08% from 2025-2031. Cardiac biomarkers are the substances that usually released into the blood when the heart is stressed or damaged. They are helpful in the diagnosis of an acute coronary syndrome (ACS) and cardiac ischemia, and other conditions associated with insufficient blood flow to the heart. The test for cardiac biomarkers is used to determine an individuals risk of having the above conditions. A cardiac biomarker is a protein-based molecule that may be quantified for heart disease prognosis and diagnosis. When the heart is injured or stressed, such as from a lack of oxygen, cardiac biomarkers are released into the bloodstream. Cardiovascular biomarkers including cardiac troponin, creatinine kinase, myoglobin, and others are used to diagnose disorders like ACS and heart ischemia.
Study Period
2025-2031Base Year
2024CAGR
10%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
Increase in the prevalence of cardiovascular diseases anticipated to drive the growth of the market. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) take the lives of 17.7 million people every year, 31% of all global deaths. Growing awareness among the people regarding the early diagnosis of the disease is expected to fuel the market. The factors such as highly accurate results and point of care testing are driving the growth of the market. However, the poor reimbursement policies are likely to hamper the growth of the market. The stringent government regulations for test approvals are hindering the growth of the cardiac biomarkers market.
Geographically, the global market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America market is the dominant market when compared with that of other regional markets owing to its deep-rooted healthcare infrastructure. The adoption of the modern diagnosis and treatment methods for cardiac disease is adding fuel for the growth of the market. Europe cardiac biomarkers market falls next to that of North America region in the global market. The Asia Pacific market is expected to grow over the forecast period owing to increase in the prevalence of the cardiac diseases. The developing healthcare infrastructure is adding fuel for the growth of the market.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 14.4 billion |
|
Market Size in 2031 |
US$ 28.2 billion |
|
Market CAGR |
10% |
|
By Biomarker Type |
|
|
By Disease Type |
|
|
By End User |
|
|
By Region |
|
Download Free Sample Report
The cardiac biomarkers market size was valued at US$ 14.4 billion in 2024 and is expected to reach US$ 28.2 billion by 2031, growing at a significant CAGR of 10.08% from 2025-2031
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
| 1. Executive Summary |
| 2. Global Cardiac Biomarkers Market Introduction |
| 2.1.Global Cardiac Biomarkers Market - Taxonomy |
| 2.2.Global Cardiac Biomarkers Market - Definitions |
| 2.2.1.Biomarker Type |
| 2.2.2.Disease Type |
| 2.2.3.End User |
| 2.2.4.Region |
| 3. Global Cardiac Biomarkers Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Cardiac Biomarkers Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Cardiac Biomarkers Market By Biomarker Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Natriuretic Peptides (BNP And NT-ProBNP) |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Ischemia Modified Albumin |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Creatine Kinase |
| 5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Myoglobin |
| 5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Troponins (T,I) |
| 5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6. Global Cardiac Biomarkers Market By Disease Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Acute Coronary Syndrome |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Congestive Heart Failure |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Atherosclerosis |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Myocardial Infarction |
| 6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7. Global Cardiac Biomarkers Market By End User, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. Laboratory Testing |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Point of Care Testing |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8. Global Cardiac Biomarkers Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. North America Cardiac Biomarkers Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 9.1. Biomarker Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Natriuretic Peptides (BNP And NT-ProBNP) |
| 9.1.2.Ischemia Modified Albumin |
| 9.1.3.Creatine Kinase |
| 9.1.4.Myoglobin |
| 9.1.5.Troponins (T,I) |
| 9.1.6.Others |
| 9.2. Disease Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Acute Coronary Syndrome |
| 9.2.2.Congestive Heart Failure |
| 9.2.3.Atherosclerosis |
| 9.2.4.Myocardial Infarction |
| 9.2.5.Others |
| 9.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Laboratory Testing |
| 9.3.2.Point of Care Testing |
| 9.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10. Europe Cardiac Biomarkers Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 10.1. Biomarker Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Natriuretic Peptides (BNP And NT-ProBNP) |
| 10.1.2.Ischemia Modified Albumin |
| 10.1.3.Creatine Kinase |
| 10.1.4.Myoglobin |
| 10.1.5.Troponins (T,I) |
| 10.1.6.Others |
| 10.2. Disease Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Acute Coronary Syndrome |
| 10.2.2.Congestive Heart Failure |
| 10.2.3.Atherosclerosis |
| 10.2.4.Myocardial Infarction |
| 10.2.5.Others |
| 10.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Laboratory Testing |
| 10.3.2.Point of Care Testing |
| 10.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11. Asia Pacific (APAC) Cardiac Biomarkers Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 11.1. Biomarker Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Natriuretic Peptides (BNP And NT-ProBNP) |
| 11.1.2.Ischemia Modified Albumin |
| 11.1.3.Creatine Kinase |
| 11.1.4.Myoglobin |
| 11.1.5.Troponins (T,I) |
| 11.1.6.Others |
| 11.2. Disease Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Acute Coronary Syndrome |
| 11.2.2.Congestive Heart Failure |
| 11.2.3.Atherosclerosis |
| 11.2.4.Myocardial Infarction |
| 11.2.5.Others |
| 11.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Laboratory Testing |
| 11.3.2.Point of Care Testing |
| 11.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12. Middle East and Africa (MEA) Cardiac Biomarkers Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 12.1. Biomarker Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Natriuretic Peptides (BNP And NT-ProBNP) |
| 12.1.2.Ischemia Modified Albumin |
| 12.1.3.Creatine Kinase |
| 12.1.4.Myoglobin |
| 12.1.5.Troponins (T,I) |
| 12.1.6.Others |
| 12.2. Disease Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Acute Coronary Syndrome |
| 12.2.2.Congestive Heart Failure |
| 12.2.3.Atherosclerosis |
| 12.2.4.Myocardial Infarction |
| 12.2.5.Others |
| 12.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Laboratory Testing |
| 12.3.2.Point of Care Testing |
| 12.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13. Latin America Cardiac Biomarkers Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 13.1. Biomarker Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Natriuretic Peptides (BNP And NT-ProBNP) |
| 13.1.2.Ischemia Modified Albumin |
| 13.1.3.Creatine Kinase |
| 13.1.4.Myoglobin |
| 13.1.5.Troponins (T,I) |
| 13.1.6.Others |
| 13.2. Disease Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Acute Coronary Syndrome |
| 13.2.2.Congestive Heart Failure |
| 13.2.3.Atherosclerosis |
| 13.2.4.Myocardial Infarction |
| 13.2.5.Others |
| 13.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Laboratory Testing |
| 13.3.2.Point of Care Testing |
| 13.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Randox laboratories (UK) |
| 14.2.2.Thermo Fisher Scientific (U.S) |
| 14.2.3.Roche Diagnostics (Switzerland) |
| 14.2.4.Abbott Laboratories (U.S) |
| 14.2.5.Siemens Healthcare (Germany) |
| 14.2.6.Alere Inc. (U.S) |
| 14.2.7.Becton, Dickinson and Company (U.S) |
| 14.2.8.Bio-Rad Laboratories (U.S) |
| 14.2.9.BioMerieux (France) |
| 14.2.10.Beckman Coulter (U.S) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
